Literature DB >> 26451535

Basal cell adenocarcinoma of the major salivary glands: A population-level study of 509 cases.

Kevin Y Zhan1, Eric J Lentsch1.   

Abstract

OBJECTIVES/HYPOTHESIS: We sought to better characterize patient, tumor, and long-term survival characteristics of basal cell adenocarcinoma (BCAC) of the major salivary glands with the National Cancer Database (NCDB). STUDY
DESIGN: Retrospective database review of the NCDB (1998-2012).
METHODS: We retrospectively reviewed the NCDB for all cases of major salivary gland BCAC with histologic code 8147/3. Relevant demographic, tumor, and survival variables were extracted and analyzed. COX multivariate regression was performed to identify prognosticators.
RESULTS: Out of 36,224 major salivary gland cancers in the NCDB, we found 509 cases of BCAC (1.4%), 88% of which were in the parotid glands, 11.2% in the submandibular glands, and 0.8% in the sublingual glands. Age at diagnosis ranged from 18 to 92 years (average 64). No gender preference was found (50.7% male). Most tumors were 2 to 4 cm in size (47.3%). Regional (11.9%) and distant metastasis (1.8%) were uncommon. Overall survival at 5 and 10 years was 79% and 62%, respectively. Although numerous variables were found to significantly impact survival on univariate regression analysis, only age ≥ 65 (hazard ratio [HR] 2.55; 95% confidence interval [CI], 1.56-4.19; P < 0.001) and high primary tumor (T)-stage (HR 1.85; 95% CI, 1.16-2.95; P = 0.010) remained significant prognosticators in our multivariate model. For high T-stage disease, surgery with radiation had significantly better survival than surgery alone.
CONCLUSION: Basal cell adenocarcinoma is a rare salivary malignancy with a good prognosis. Regional and distant metastasis were uncommon. Radiation with surgery may help for higher T-stage disease. Old age and high T-stage were significant predictors of worse survival. LEVEL OF EVIDENCE: 4. Laryngoscope, 126:1086-1090, 2016.
© 2015 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Basal cell adenocarcinoma; basal cell adenoma; head and neck cancer; parotid cancer; salivary gland cancer

Mesh:

Year:  2015        PMID: 26451535     DOI: 10.1002/lary.25713

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  High-Grade Basal Cell Adenocarcinoma Arising from the Parotid Gland: A Case Report and Review of the Literature.

Authors:  Çağatay Han Ülkü; Pembe Oltulu; Mustafa Cihat Avunduk
Journal:  Turk Arch Otorhinolaryngol       Date:  2017-12-01

2.  Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study.

Authors:  Yuzo Oyama; Haruto Nishida; Takahiro Kusaba; Hiroko Kadowaki; Motoki Arakane; Junpei Wada; Shogo Urabe; Takashi Hirano; Kenji Kawano; Masashi Suzuki; Shigeo Yokoyama; Tsutomu Daa
Journal:  Diagn Pathol       Date:  2018-07-27       Impact factor: 2.644

3.  Metachronous malignant tumors in ipsilateral salivary glands.

Authors:  Hyo Jeong Kwon; Seong Ae Kim; Jong Won Rhie; Suk-Ho Moon
Journal:  Arch Craniofac Surg       Date:  2019-12-20

Review 4.  Basal cell adenocarcinoma of the nasopharyngeal minor salivary glands: a case report and review of the literature.

Authors:  Jia Jin; Xia-Yun He
Journal:  BMC Cancer       Date:  2018-09-10       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.